Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Price Target of $51.75 According to Analysts

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $51.00.

A number of research firms have recently weighed in on JBIO. Guggenheim lowered their price target on shares of Jade Biosciences from $47.00 to $41.00 and set a “buy” rating on the stock in a research note on Monday. Wall Street Zen upgraded shares of Jade Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 14th. Jefferies Financial Group reissued a “buy” rating and set a $48.00 price objective on shares of Jade Biosciences in a report on Tuesday, August 11th. BTIG Research restated a “buy” rating on shares of Jade Biosciences in a research report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Jade Biosciences in a report on Thursday, October 1st.

Check Out Our Latest Research Report on Jade Biosciences

Jade Biosciences Trading Up 0.6%

NASDAQ JBIO opened at $15.49 on Friday. The business’s 50 day moving average is $15.08 and its two-hundred day moving average is $18.14. Jade Biosciences has a 12-month low of $11.02 and a 12-month high of $28.00.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.31. Research analysts anticipate that Jade Biosciences will post -2.62 earnings per share for the current year.

Key Stories Impacting Jade Biosciences

Here are a few of the latest stories about JBIO:

  • Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.25 from $2.41 per share, implying a smaller expected loss. It kept its Buy rating and $55 price target. Jade Biosciences analyst estimates
  • Positive Sentiment: Wall Street Zen upgraded JBIO, while a separate report said analysts’ overall view was “Moderate Buy”—a supportive, though not unanimous, signal. Wall Street Zen upgrade Analyst consensus rating
  • Negative Sentiment: Guggenheim issued a report described as a “pessimistic forecast” for JBIO, adding a cautious analyst signal; the provided headline did not specify its assumptions or price target. Guggenheim forecast

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of JBIO. Bellevue Group AG boosted its position in Jade Biosciences by 40.4% during the 3rd quarter. Bellevue Group AG now owns 4,293,937 shares of the company’s stock worth $60,330,000 after purchasing an additional 1,235,941 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Jade Biosciences during the first quarter worth about $43,557,000. Pictet Asset Management Holding SA boosted its position in shares of Jade Biosciences by 64.4% in the third quarter. Pictet Asset Management Holding SA now owns 1,205,972 shares of the company’s stock worth $16,944,000 after buying an additional 472,204 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Jade Biosciences by 22.0% in the third quarter. Goldman Sachs Group Inc. now owns 896,834 shares of the company’s stock worth $12,601,000 after buying an additional 161,610 shares during the period. Finally, Jump Financial LLC boosted its position in shares of Jade Biosciences by 75.3% in the third quarter. Jump Financial LLC now owns 302,812 shares of the company’s stock worth $4,255,000 after buying an additional 130,065 shares during the period.

Jade Biosciences Company Profile

(Get Free Report)

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.

Featured Articles

Analyst Recommendations for Jade Biosciences (NASDAQ:JBIO)

Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.